Trial intelligence / Profile preview

BOTOX for urinary incontinence due to overactive bladder in adolescents

2014-000464-17Phase 3Unknown

Sponsor
Allergan
Start
Apr 2014
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, single-arm trial of botulinum toxin type A in overactive bladder (OAB), sponsored by Allergan. Primary endpoint: Number of daytime urinary incontinence episodes. Status: unknown.

02

Drugs

botulinum toxin type A
03

Conditions

overactive bladder (OAB)

Beyond the preview

Go deeper on 2014-000464-17.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-000464-17.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call